CommercialCoverageMedium impact
Body Surface Potential Mapping (CPB 0705, reviewed 2026-10-14)
Aetna·Cardiology, Critical Care, Internal Medicine·Medical Policy
We identified it
Oct 15, 2026
Summary
Aetna's Clinical Policy Bulletin 0705 (reviewed 2026-10-14) classifies body surface potential mapping (BSPM) as experimental, investigational, or unproven for five cardiac indications: acute coronary syndromes, atrial fibrillation, Brugada syndrome, atrial fibrillation ablation guidance, and cardiac resynchronization therapy response prediction. CPT codes 0695T and 0696T are not covered for these indications. This is a standing coverage policy with no new effective date; practices should verify current applicability and confirm whether claims for BSPM have been previously denied or require prior authorization under this classification.
Action Required
Verify whether the practice has implemented denial protocols or prior authorization requirements for CPT codes 0695T and 0696T (body surface–activation mapping) when submitted for the five non-covered indications listed (acute coronary syndromes, atrial fibrillation, Brugada syndrome, atrial fibrillation ablation guidance, cardiac resynchronization therapy response prediction). Billing team should: (1) confirm current applicability of this standing Aetna policy; (2) ensure billing software flags claims for these codes with these diagnoses for potential denial; (3) educate cardiology and electrophysiology providers that BSPM is classified as experimental for these indications and will not be covered by Aetna; (4) advise patients in advance if BSPM is requested, as they may be liable for out-of-pocket costs. Related pacemaker and defibrillator CPT/HCPCS codes (33208–33264, 93000–93297, 93641, 93653–93657, C7537–C7540) remain covered when used for covered indications; verify that claims using these codes do not inappropriately trigger denials.